Share

Health policies and data

Addressing the challenges of access to medicines

 

 

Exploring further policy options suggested in the report Pharmaceutical Innovation and access to medicines (forthcoming), the OECD has undertaken, with the financial support of the EU Health Programme, several projects to further identify avenues to increase pharmaceutical expenditure efficiency and better prepare to changes in the market. 

 

 

 

EU-co-funded

Access-to-medicines

KEY THEMES

Using routinely collected data to inform pharmaceutical policies

This project aims to describe best practices in the use of information routinely collected in health systems to improve knowledge on the performance of medicines in real settings and increase spending efficiency. It is based on research, a survey of OECD and EU countries, and interviews.
The Analytical Report and the Country Notes were released on February 28, 2019:

Better anticipating pharmaceutical market dynamics

This project aims to help countries better anticipating dynamics in pharmaceutical markets (new entrants, end of market/data exclusivity). It is based on research, a country survey, and interviews.
The final Report and the Country Notes were released on April 30, 2019:

Building capacities for improved pricing and reimbursement negotiations

In many OECD and EU countries, medicines are largely financed by government or compulsory health insurance schemes. Coverage and pricing decisions are made at central level and sometimes entail a negotiation with pharmaceutical companies. The negotiators’ objective is to pay for value but they are unequally equipped to achieve this results. This project will mainly consist of experience-sharing and include a focus on performance-based agreements.
The final report will be published at the end of 2019.

Addressing the specific challenge of pricing of oncology treatments

Oncology treatments are proliferating. They increasingly target small population groups and bring tremendous benefits for some of them. One particular feature of oncology medicines is that they are often used in associations with other products, potentially marketed by different companies. Setting prices for individual products has become increasingly difficult. This project will explore new avenues to pay for oncology treatments.
The final report will be published at the end of 2019.
 

FURTHER READING

CONTACT US

‌ Small follow us Twitter icon‌ 
Follow us on Twitter @OECD_Social

 

Related Documents